ReviewStem cell research & therapy2025
Potential MiRNA therapies for premature ovarian failure: new challenges and opportunities.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From Genes to Lives: Integrating the Complexities of Primary Ovarian Insufficiency.International journal of molecular sciences · 2026Review
- Molecular mechanisms underlying cyclophosphamide-induced ovarian injury and protective strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- MicroRNA Crossroads in PCOS and Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- MicroRNAs Regulating Oxidative Stress in Human Fertility: A Narrative Review of Mechanistic Insights and Clinical Potential.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature ovarian failure (POF) is characterized by decreased ovarian function in women under 40 years of age, which leads to amenorrhea and infertility. This condition is commonly associated with diverse symptoms related to hormonal deficiency. The individuals with POF are also at an increased risk of developing several systemic conditions, including osteoporosis, neurological issues, and cardiovascular diseases. POF significantly impacts a woman’s reproductive health, fertility, and overall quality of life. The current treatments for POF primarily include hormone replacement therapy (HRT) and ovulation induction, although these approaches have significant limitations. Recent advances in relevant research have highlighted the therapeutic potential of microRNAs (miRNAs), which exhibit promising outcomes in preventing granulosa cell (GC) apoptosis, enhancing hormonal secretion, mitigating oxidative stress, and promoting angiogenesis. This review focuses on the significance of exosomal miRNAs in POF management, particularly their roles in preventing GC apoptosis and restoring ovarian function. The objective is to guide the future clinical trials and therapeutic applications and thereby advance the research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.